OBJECTIVE: As glucagon-like peptide-1 receptor agonists lower blood pressure (BP) in type 2 diabetes mellitus (T2DM), we examined BP control in relation to targets set by international bodies prior to randomization in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial. METHODS: We analyzed baseline data from LEADER (NCT01179048), an ongoing phase 3B, randomized, double-blind, placebo-controlled cardiovascular outcomes trial examining the cardiovascular safety of the glucagon-like peptide-1 receptor agonist liraglutide in 9340 people with T2DM from 32 countries [age (all mean ± SD) 64 ± 7.2 years, BMI 32.5 ± 6.3 kg/m, duration of diabetes 12.7 ± 8.0 years], all of whom were at high risk for cardiovascular disease (CVD). RESULTS: A total of 81% (n = 7592) of participants had prior CVD and 90% (n = 8408) had a prior history of hypertension. Despite prescription of multiple antihypertensive agents at baseline, only 51% were treated to a target BP of less than 140/85 mmHg and only 26% to the recommended baseline BP target of less than 130/80 mmHg. In univariate analyses, those with prior CVD were prescribed more agents (P < 0.001) and had lower BP than those without (137 ± 18.8/78 ± 10.6 mmHg versus 140 ± 17.7/80 ± 9.9 mmHg; P < 0.001). In logistic regression analyses, residency in North America (64% treated to <140/85 mmHg; 38% treated to <130/80 mmHg) was the strongest predictor of BP control. CONCLUSION: These contemporary data confirm that BP remains insufficiently controlled in a large proportion of individuals with T2DM at high cardiovascular risk, particularly outside North America. Longitudinal data from the LEADER trial may provide further insights into BP control in relation to cardiovascular outcomes in this condition.

Institute of Cardiovascular and Medical Sciences University of Glasgow Glasgow UK bDivision of Cardiology Department of Internal Medicine University of Texas Southwestern Dallas Texas USA cInstitute of Life Science College of Medicine Swansea University Medical School Swansea UK dMossakowski Medical Research Centre Polish Academy of Sciences eDepartment of Internal Diseases Endocrinology and Diabetology Central Clinical Hospital MSW Warsaw Poland fKardio Metabolischen Instituts Villingen Schwenningen Germany gEndocrinology and Nutrition Department Hospital Son Llàtzer University Institute of Health Science Research Universitat de les Illes Balears Palma de Mallorca Spain hDivisions of Endocrinology and Metabolism Li Ka Shing Knowledge Institute and Keenan Research Centre for Biomedical Science St Michael's Hospital University of Toronto Ontario Canada i1st Faculty of Medicine and General University Hospital Charles University Prague Prague Czech Republic jDivision of Endocrinology and Metabolism Istanbul Faculty of Medicine Istanbul University Istanbul Turkey kDepartment of Diabetes and Endocrinology Nelson R Mandela School of Medicine University of KwaZulu Natal South Africa lEndocrinology Research Centre Diabetes Institute mI M Sechenov 1st Moscow State Medical University Moscow Russian Federation nFaculty of Medicine Antwerp University Hospital Antwerp Belgium oDepartment of Nephrology Hypertension and Rheumatology Friedrich Alexander University of Erlangen Munchen Germany pNovo Nordisk A S Bagsvaerd Denmark qLunenfeld Tanenbaum Research Institute Mount Sinai Hospital University of Toronto Toronto Canada rInternational Centre for Circulatory Health Imperial College London London UK

Zobrazit více v PubMed

UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703–713. PubMed PMC

Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, et al. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370:829–840. PubMed

Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. Eur Heart J 2007; 28:1462–1536. PubMed

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42:1206–1252. PubMed

Bakris G, Sarafidis P, Agarwal R, Ruilope L. Review of blood pressure control rates and outcomes. J Am Soc Hypertens 2014; 8:127–141. PubMed

Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895–906. PubMed

Marso SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH, et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J 2013; 166:823–830. PubMed

Reisin E, Graves JW, Yamal JM, Barzilay JI, Pressel SL, Einhorn PT, et al. Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT. J Hypertens 2014; 32:1503–1513. PubMed PMC

Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH. Weight and blood pressure. Findings in hypertension screening of 1 million Americans. JAMA 1978; 240:1607–1610. PubMed

Ismail-Beigi F. Clinical practice. Glycemic management of type 2 diabetes mellitus. N Engl J Med 2012; 366:1319–1327. PubMed

Petrie JR, Adler A, Vella S. What to add in with metformin in type 2 diabetes? QJM 2011; 104:185–192. PubMed

Petrie JR. The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovasc Diabetol 2013; 12:130–142. PubMed PMC

Clar C, Gill JA, Court R, Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2: pii e001007. PubMed PMC

Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Strand J, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26:268–278. PubMed PMC

Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32:84–90. PubMed PMC

Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373:473–481. PubMed

Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009; 32:1224–1230. PubMed PMC

Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52:2046–2055. PubMed PMC

Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121–2158. PubMed

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281–1357. PubMed

American Diabetes Association. Standards of medical care in diabetes – 2015. Diabetes Care 2015; 38 Suppl. 1:S1–S93. PubMed

White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369:1327–1335. PubMed

Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369:1317–1326. PubMed

Mosenzon O, Raz I, Scirica BM, Hirshberg B, Stahre CI, Steg PG, et al. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial. Diabetes Metab Res Rev 2013; 29:417–426. PubMed

ACCORD study group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575–1585. PubMed PMC

Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373:2125–2135. PubMed

Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet 2005; 366:1279–1289. PubMed

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837–853. PubMed

Bethel MA, Green JB, Milton J, Tajar A, Engel SS, Califf RM, Holman RR. TECOS Executive Committee. Regional, age and sex differences in baseline characteristics of patients enrolled in the trial evaluating cardiovascular outcomes with sitagliptin (TECOS). Diabetes Obes Metab 2015; 17:395–402. PubMed

White WB, Turner JR, Sica DA, Bisognano JD, Calhoun DA, Townsend RR, et al. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A. J Am Soc Hypertens 2014; 8:743–757. PubMed

Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289:2363–2369. PubMed

Danaei G, Finucane MM, Lin JK, Singh GM, Paciorek CJ, Cowan MJ, et al. Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Pressure). National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5·4 million participants. Lancet 2011; 377:568–577. PubMed

Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43:10–17. PubMed

ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 2013; 31:1925–1938. PubMed

James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507–520. PubMed

American Diabetes Association. Standards of medical care in diabetes 2014. Diabetes Care 2014; 37 Suppl 1:S14–S80. PubMed

Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009; 18:308–347. PubMed

Rückert IM, Baumert J, Schunk M, Holle R, Schipf S, Völzke H, et al. Blood pressure control has improved in people with and without type 2 diabetes but remains suboptimal: a longitudinal study based on the German DIAB-CORE consortium. PLoS One 2015; 10:e0133493. PubMed PMC

Mourad JJ, Le Jeune S. Blood pressure control, risk factors and cardiovascular prognosis in patients with diabetes: 30 years of progress. J Hypertens Suppl 2008; 26:S7–13. PubMed

Borzecki AM, Berlowitz DR. Management of hypertension and diabetes: treatment goals, drug choices, current practice, and strategies for improving care. Curr Hypertens Rep 2005; 7:439–449. PubMed

Eguchi K, Pickering TG, Kario K. Why is blood pressure so hard to control in patients with type 2 diabetes? J Cardiometab Syndr 2007; 2:114–118. PubMed

Wright JT, Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373:2103–2116. PubMed PMC

Agnoletti D, Lieber A, Zhang Y, Protogerou AD, Borghi C, Blacher J, Safar ME. Central hemodynamic modifications in diabetes mellitus. Atherosclerosis 2013; 230:315–321. PubMed

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:2117–2128. PubMed

Wilding JP. The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism 2014; 63:1228–1237. PubMed

Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373:2247–2257. PubMed